UY24206A1 - Feniliminoimidazolinas agonistas de alfa 1l útiles en el tratamiento de la incontinencia urinaria. - Google Patents

Feniliminoimidazolinas agonistas de alfa 1l útiles en el tratamiento de la incontinencia urinaria.

Info

Publication number
UY24206A1
UY24206A1 UY24206A UY24206A UY24206A1 UY 24206 A1 UY24206 A1 UY 24206A1 UY 24206 A UY24206 A UY 24206A UY 24206 A UY24206 A UY 24206A UY 24206 A1 UY24206 A1 UY 24206A1
Authority
UY
Uruguay
Prior art keywords
alkyl
alpha
treatment
urinary incontinence
imidazoline
Prior art date
Application number
UY24206A
Other languages
English (en)
Inventor
Dr Shuji M D Uchida
Dr Hisato Kitagawa
Prof Ikunobu Muramatsu
Dr Sven Luttke
Dr Helmut Stahle
Dr Franz Esser
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of UY24206A1 publication Critical patent/UY24206A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de fórmula general Ib o II representados en la figura 1 o una sal farmacéuticamente aceptable de los mismos, donde: R1 es H, alquilo, cicloalquilo, alcoxi, halógeno, CF3 o OCF3; R2 es NR6R7, donde R6 es alquilo y R7 es alquilo o acilo; R3 y R5 independientemente entre si son H, halógeno, alquilo, alcoxi, -CF3 o OCF3; R4 es H, halógeno o alquilo; se excluye la 2-(3-dietilamino-2-metilfenilamino)-imidazolina y la 2-(3-dimetilamino-2,6-diclorofenilamino)-imidazolina. Ejemplos de compuestos de fórmula Ib o II: 2-(4,6-dibromo-3-dimetilamino-2-metilfenilimino)-imidazolidina; 2-(4-bromo-3-dimetilamino-2-metilfenilimino)-imidazolina, y sus sales de adición farmacológicamente aceptables; entre otros. Estos compuestos son agonistas de alfa 1L por tanto son útiles para el tratamiento de la incontinencia urinaria. También es incluido un procedimiento para la preparación de un preparado farmacéutico, caracterizado porque se mezcla un compuesto de fórmula Ib o II con excipientes galénicos convencionales y/o vehículos usuales.
UY24206A 1995-04-20 1996-04-14 Feniliminoimidazolinas agonistas de alfa 1l útiles en el tratamiento de la incontinencia urinaria. UY24206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19514579A DE19514579A1 (de) 1995-04-20 1995-04-20 Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz

Publications (1)

Publication Number Publication Date
UY24206A1 true UY24206A1 (es) 2000-08-21

Family

ID=7759982

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24206A UY24206A1 (es) 1995-04-20 1996-04-14 Feniliminoimidazolinas agonistas de alfa 1l útiles en el tratamiento de la incontinencia urinaria.

Country Status (31)

Country Link
US (4) US6268389B1 (es)
EP (2) EP0821585B1 (es)
JP (2) JP3379960B2 (es)
KR (1) KR19990007985A (es)
CN (1) CN1119148C (es)
AR (1) AR002043A1 (es)
AU (1) AU719710B2 (es)
BG (1) BG64116B1 (es)
BR (1) BR9608049A (es)
CA (1) CA2214338C (es)
CZ (1) CZ327197A3 (es)
DE (2) DE19514579A1 (es)
EE (1) EE04416B1 (es)
ES (1) ES2279521T3 (es)
HR (1) HRP960187A2 (es)
HU (1) HUP9801599A3 (es)
IL (1) IL117956A (es)
MX (1) MX9707570A (es)
NO (1) NO974821D0 (es)
NZ (1) NZ307509A (es)
PE (1) PE44297A1 (es)
PL (1) PL184881B1 (es)
RU (2) RU2230061C2 (es)
SK (1) SK138097A3 (es)
TR (1) TR199701212T1 (es)
TW (1) TW403739B (es)
UA (1) UA62913C2 (es)
UY (1) UY24206A1 (es)
WO (1) WO1996032939A1 (es)
YU (1) YU24496A (es)
ZA (1) ZA963131B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
GB9906192D0 (en) 1999-03-18 1999-05-12 Medical Res Council Photoreleasable compounds
US6323231B1 (en) 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence
WO2002032876A2 (de) * 2000-10-14 2002-04-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue m-amino-phenylimino-imidazolidin-derivate zur behandlung der harninkontinenz
US6602897B2 (en) 2000-10-14 2003-08-05 Boehringer Ingelheim Pharma Kg m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence
GB0030580D0 (en) * 2000-12-15 2001-01-31 Medicare Man Consultancy Ltd Composition and method
US6660772B2 (en) 2001-02-01 2003-12-09 Boehringer Ingelheim Pharma Kg Use of 2-amino-1-(4-hydroxy-2-methanesulfonamidophenyl)ethanol for treating urinary incontinence
DE10104369A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Verwendung von 2-Amino-(4-hydroxy-2-methansulfonamidophenyl)ethanol zur Behandlung der Harninkontinenz
US20020169193A1 (en) * 2001-02-10 2002-11-14 Pascale Pouzet Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence
DE10106214A1 (de) * 2001-02-10 2002-08-14 Boehringer Ingelheim Pharma Neue Alkyl-phenylimino-imidazolidin-Derivate zur Behandlung der Harninkontinenz
GB0114008D0 (en) * 2001-06-08 2001-08-01 Perry Robert E New therapautic use
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US6703409B2 (en) 2002-01-31 2004-03-09 Boehringer Ingelheim Pharma Gmbh & Co Kg 2′-Halo-3′,5′-dialkoxyphen-1′-yl-imino-2-imidazolidine and the use thereof as a drug
EP1333028A1 (en) * 2002-01-31 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
JP4209332B2 (ja) * 2002-02-01 2009-01-14 エフ．ホフマン−ラ ロシュ アーゲー α−１アゴニストとしての置換インドール
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
JP5248528B2 (ja) 2007-02-02 2013-07-31 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ疾患用のｔａａｒ１リガンドとしての新規２−アミノオキサゾリン
CA2676944C (en) * 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
JP2010535172A (ja) * 2007-08-02 2010-11-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置のためのベンズアミド誘導体の使用
CA2696404A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Therapeutic compounds
WO2009023758A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Heterocyclyl substituted fused carbocyles useful in the treatment of conditions such as glaucoma and pain
JP4168086B1 (ja) * 2008-04-16 2008-10-22 国立大学法人福井大学 イミダゾリン誘導体
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
CN102083805A (zh) * 2008-07-24 2011-06-01 弗·哈夫曼-拉罗切有限公司 4,5-二氢-唑-2-基衍生物
GB2466622A (en) * 2008-12-23 2010-06-30 Trinity College Dublin Alpha2-Adrenoceptor Ligands
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2012008565A1 (ja) * 2010-07-16 2012-01-19 日本ケミファ株式会社 イミダゾリン誘導体
ME02663B (me) 2010-10-06 2017-06-20 Glaxosmithkline Llc Derivati benzimidazola kao inhibitori pi3 kinaze
JPWO2015152196A1 (ja) * 2014-03-31 2017-04-13 東レ株式会社 イミダゾリン誘導体及びその医薬用途
SG11201807516UA (en) 2016-03-17 2018-09-27 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899426A (en) * 1959-08-11 Synthesis of l
DE71554C (de) * B. BROCKHUES, in Firma BROCKHUES & ClE, in Köln a. Rh Leicht transportable Nothlaschung für Schienenbrüche
US2744910A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2915431A (en) * 1956-07-17 1959-12-01 Lab Robert & Carriere Sa Des 2-(2'-isopropyl-4'-chloro-5'-methyl)-phenoxymethyl-2-imidazoline and its pharmaceutical uses
US3081222A (en) * 1960-03-11 1963-03-12 Us Rubber Co Fungicides
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
AT285599B (de) 1968-06-21 1970-11-10 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen trisubstituierten 2-Arylaminoimidazolinen und ihren Salzen
BE754935A (fr) * 1969-08-13 1971-02-17 Hoechst Ag 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation
DE2316377C3 (de) 1973-04-02 1978-11-02 Lentia Gmbh, Chem. U. Pharm. Erzeugnisse - Industriebedarf, 8000 Muenchen Verfahren zur Herstellung von 2-Phenyl-amino-2-imidazolin-Derivaten und von deren Salzen
FR2269341B1 (es) * 1974-04-30 1978-07-28 Castaigne Sa
MTP837B (en) * 1977-11-07 1979-10-22 Hoffman La Roche And Co Aktien Derivatives 2 finino-imidazolidire
DE2806811A1 (de) 1978-02-17 1979-08-23 Boehringer Sohn Ingelheim Neue substituierte 2-phenylimino- imidazolidine, deren saeureadditionssalze, diese enthaltene arzneimittel und verfahren zur herstellung derselben
DE2806775A1 (de) * 1978-02-17 1979-08-30 Boehringer Sohn Ingelheim Neue substituierte 2-phenylimino- imidazolidine deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben
DE2811847A1 (de) 1978-03-17 1979-09-20 Lentia Gmbh Neue arylaminoimidazolinderivate, deren herstellung und verwendung als arzneimittel
US4226713A (en) 1978-04-24 1980-10-07 Goldberg Jack M Diagnostic agents
US4262005A (en) * 1978-05-31 1981-04-14 The Boots Company Limited Compounds, compositions and methods for controlling pests
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE2854659A1 (de) * 1978-12-18 1980-07-10 Boehringer Sohn Ingelheim Neue 3,4-disubstituierte 2-phenylimino-imidazolidine, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
US4226773A (en) * 1979-05-07 1980-10-07 Abbott Laboratories Pyrazolyl amino imidazolines as diuretic agents
DE2949287A1 (de) 1979-12-07 1981-06-11 C.H. Boehringer Sohn, 6507 Ingelheim Neue substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben
US4287201A (en) * 1980-03-03 1981-09-01 Merck & Co., Inc. Anovulatory method and chicken feed compositions
DE3168754D1 (en) * 1980-07-09 1985-03-21 Beecham Group Plc Clonidine derivatives useful in the treatment of diarrhoea
EP0070084A3 (en) * 1981-04-24 1983-02-16 Beecham Group Plc Imidazoline derivatives
DE3133886A1 (de) 1981-08-27 1983-03-17 Bayer Ag, 5090 Leverkusen 2-arylazo-2-imidazoline, acylderivate derselben, verfahren zu ihrer herstellung und die verwendung zur bekaempfung von ekto- und/oder endoparasiten
CA1201066A (en) * 1981-11-20 1986-02-25 Alcon Laboratories, Inc. N-¬3,5-dichloro-4-(2-imidazolidinylideneamino)- phenyl|-acetamide solutions for lowering intraocular pressure
US4644007A (en) 1981-11-20 1987-02-17 Alcon Laboratories, Inc. 3-chloro-4-(4,5-dihydro-1H-imidazo-2-yl)-amino-5-alkylbenzoic acids, esters, salts, compositions and methods
US4517199A (en) * 1981-11-20 1985-05-14 Alcon Laboratories, Inc. Method for lowering intraocular pressure using phenylimino-imidazoles
US4461904A (en) * 1981-11-20 1984-07-24 Alcon Laboratories, Inc. 2-(Trisubstituted phenylimino)-imidazolines
FR2521140A1 (fr) 1982-02-05 1983-08-12 Synthelabo Derives d'imidazolidine, leur preparation et leur application en therapeutique
GB8304593D0 (en) 1983-02-18 1983-03-23 Beecham Group Plc Amidines
GB8333835D0 (en) * 1983-12-20 1984-02-01 Beecham Group Plc Compounds
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives
EP0236636A3 (en) * 1986-02-07 1988-12-07 Alcon Laboratories, Inc. Use of clonidine derivatives for the preparation of ocular hemostatic agents
US4861904A (en) * 1986-04-17 1989-08-29 Agency Of Industrial Science And Technology Schiff base metal complex compounds, and organometallic ultrathin film composed thereof and oxygen separation films composed thereof
GB8610909D0 (en) * 1986-05-03 1986-06-11 Beecham Group Plc Compounds
US4861189A (en) 1987-02-26 1989-08-29 Kajima Corporation System for paving inclined and/or curved surfaces
US4801617A (en) * 1987-04-06 1989-01-31 Leclerc Gerard Iminoimidazolidines useful in lowering intraocular pressure
DE3712385A1 (de) * 1987-04-11 1988-10-27 Boehringer Ingelheim Kg 2-(phenylimino)imidazolidine
JPH078795B2 (ja) * 1989-09-06 1995-02-01 日立化成工業株式会社 排尿障害治療剤
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
IE911994A1 (en) * 1990-07-03 1992-01-15 Akzo Nv 5-isothiazolamine derivatives
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
US5237032A (en) 1992-09-30 1993-08-17 Istituto Guido Donegani S.P.A. Microwave processing of carbonate monomers
EP0599697A1 (fr) * 1992-11-24 1994-06-01 Synthelabo Dérivés de pyrrole, leur préparation et leur application en thérapeutique
US5447916A (en) * 1993-07-30 1995-09-05 Chiron Corporation Peptoid alpha-1 adrenergic receptor ligands
CA2181909C (en) 1994-01-24 2008-10-07 Stephen A. Munk Aromatic 2-amino-imidazole derivatives as alpha-2a adrenoceptor agonists
FR2719844B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-thiéno[3,4-c]pyrrole, leur préparation et leur application en thérapeutique.
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6602897B2 (en) * 2000-10-14 2003-08-05 Boehringer Ingelheim Pharma Kg m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence

Also Published As

Publication number Publication date
PL324041A1 (en) 1998-05-11
CA2214338A1 (en) 1996-10-24
US7019021B2 (en) 2006-03-28
HUP9801599A3 (en) 1999-04-28
BG101966A (en) 1998-09-30
US20040198796A1 (en) 2004-10-07
DE19514579A1 (de) 1996-10-24
US6268389B1 (en) 2001-07-31
EP0821585B1 (de) 2007-01-10
JP4141763B2 (ja) 2008-08-27
NO974821L (no) 1997-10-17
BG64116B1 (bg) 2004-01-30
US20020040150A1 (en) 2002-04-04
CA2214338C (en) 2010-10-19
AR002043A1 (es) 1998-01-07
RU2230061C2 (ru) 2004-06-10
JPH11503738A (ja) 1999-03-30
PL184881B1 (pl) 2003-01-31
JP2003064058A (ja) 2003-03-05
AU5687896A (en) 1996-11-07
AU719710B2 (en) 2000-05-18
CZ327197A3 (cs) 1998-05-13
IL117956A0 (en) 1996-08-04
ES2279521T3 (es) 2007-08-16
EE04416B1 (et) 2005-02-15
BR9608049A (pt) 1999-01-26
KR19990007985A (ko) 1999-01-25
RU2003104267A (ru) 2004-08-27
WO1996032939A1 (de) 1996-10-24
US20030114425A1 (en) 2003-06-19
TW403739B (en) 2000-09-01
YU24496A (sh) 1998-12-23
IL117956A (en) 2001-11-25
MX9707570A (es) 1997-12-31
NZ307509A (en) 2000-06-23
EP0821585A1 (de) 1998-02-04
TR199701212T1 (xx) 1998-03-21
EP1285653A1 (de) 2003-02-26
EE9700267A (et) 1998-06-15
US6858594B2 (en) 2005-02-22
HUP9801599A2 (hu) 1999-01-28
CN1180311A (zh) 1998-04-29
CN1119148C (zh) 2003-08-27
JP3379960B2 (ja) 2003-02-24
UA62913C2 (en) 2004-01-15
SK138097A3 (en) 1998-02-04
NO974821D0 (no) 1997-10-17
DE59611411D1 (de) 2007-02-22
PE44297A1 (es) 1997-10-27
HRP960187A2 (en) 1997-12-31
ZA963131B (en) 1996-10-21

Similar Documents

Publication Publication Date Title
UY24206A1 (es) Feniliminoimidazolinas agonistas de alfa 1l útiles en el tratamiento de la incontinencia urinaria.
NO2005024I1 (no) Heksylaminolevulinat, eventuelt i form av et salt,fortinnsvis heksylaminolevulinathydroklorid
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
CO4410181A1 (es) Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol
KR900007790A (ko) 항-아테롬성 동맥경화증성 디아릴 화합물
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
NO20021879L (no) Bisykliske vasopressinagonister
LV10607A (lv) Jauni bicikliski aminoaizvietoti savienojumi
NO167286C (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzotiazepin-derivater.
ES2182509T3 (es) Derivados de n-ariloxietilamina para el tratamiento de la depresion.
GB8320005D0 (en) Benzothiazoline derivatives
ES548878A0 (es) Un procedimiento para la preparacion de una forma polimorfo i de una sal de monoetanolamina
FI960730A0 (fi) Indolijohdannaiset 5alfa-reduktaasi-1-inhibiittoreina
NO840732L (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n-(3-trifluormetylfenyl)-n`-propargylpiperazin
GB9420503D0 (en) Therapeutic agents
SE8705196L (sv) Pyrimidinderivat
PE20001647A1 (es) Derivados de 3-amino-3-arilpropano-1-ol y procedimiento de preparacion de los mismos
DE3068456D1 (en) 2-(n-(2-fluoro-6-bromophenyl)-n-(thiemyl-2-methyl)-amino)-2-imidazoline, its addition salts, pharmaceutical compositions containing them and processes for their preparation
HU9202462D0 (en) Method for producing new 2-imidazolyl derivatives of substituted bicyclic compounds and pharmaceutical preparatives containing them as active agent
CO4761062A1 (es) Procedimientos para inhibir tumores de colon
UY24199A1 (es) Nuevos derivados de etanolamina
SE8303718L (sv) E-homo-enurnanderivat, forfarande for framstellning derav samt farmaceutiska kompositioner innehallande dessa foreningar
CO5300520A1 (es) Nuevos compuestos de sulfonamida y usos de los mismos
RU97113694A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для сосудорасширяющего лечения или профилактики

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20160414